[Urology in 2011].
In 2011, therapeutic acquisitions in urology allow optimizing management of acute uncomplicated cystitis and acute pyelonephritis by female patients and in men clinical implications of benign prostatic hyperplasia opposed to prostate cancer detection as well as hormonal treatment of advanced prostate cancer.
Service d'urologie, CHUV, 1011 Lausanne. patrice.jichlinski@chuv.ch
P
P
Jichlinski
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000628:therapy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy; D011704:Pyelonephritis / Q000188:drug therapy; D016896:Treatment Outcome; D014572:Urology / Q000639:trends*
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D018931:Antineoplastic Agents, Hormonal; D002939:Ciprofloxacin